Refludan

RSS

Withdrawn

This medicine's authorisation has been withdrawn

lepirudin
MedicineHumanWithdrawn

Irish is available via eTranslation, the European Commission's machine translation service.

Translate to Irish | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 13 March 1997 the European Commission issued a marketing authorisation valid throughout the European Union for the medicinal product Refludan (lepirudin). Refludan was approved for anticoagulation in adult patients with heparin-induced thrombocytopenia (HAT) type II and thromboembolic disease mandating parenteral antithrombotic therapy. The marketing authorisation holder (MAH) responsible for Refludan was Celgene Europe Ltd. The European Commission was notified by 3 letters dated 31 March 2012, 2 April 2012 and 30 April 2012 of the MAH’s decision to voluntarily withdraw the marketing authorisation for Refludan for commercial reasons. 

On 24 April 2012 the European Commission issued a decision to withdraw the marketing authorisation for Refludan. Pursuant to this decision the European Public Assessment Report for Refludan is updated to reflect the fact that the marketing authorisation is no longer valid.

български (BG) (429.25 KB - PDF)

Amharc

español (ES) (264.03 KB - PDF)

Amharc

čeština (CS) (400.71 KB - PDF)

Amharc

dansk (DA) (262.07 KB - PDF)

Amharc

Deutsch (DE) (263.26 KB - PDF)

Amharc

eesti (ET) (262.89 KB - PDF)

Amharc

ελληνικά (EL) (398.18 KB - PDF)

Amharc

français (FR) (265.03 KB - PDF)

Amharc

italiano (IT) (264.33 KB - PDF)

Amharc

latviešu (LV) (406.2 KB - PDF)

Amharc

lietuvių (LT) (379.07 KB - PDF)

Amharc

magyar (HU) (392.49 KB - PDF)

Amharc

Malti (MT) (403.96 KB - PDF)

Amharc

Nederlands (NL) (264.24 KB - PDF)

Amharc

polski (PL) (409.22 KB - PDF)

Amharc

português (PT) (264.41 KB - PDF)

Amharc

română (RO) (371.68 KB - PDF)

Amharc

slovenčina (SK) (396.91 KB - PDF)

Amharc

slovenščina (SL) (387.06 KB - PDF)

Amharc

suomi (FI) (263.77 KB - PDF)

Amharc

svenska (SV) (264.23 KB - PDF)

Amharc

Product information

български (BG) (1.53 MB - PDF)

Amharc

español (ES) (703.63 KB - PDF)

Amharc

čeština (CS) (1.18 MB - PDF)

Amharc

dansk (DA) (696.12 KB - PDF)

Amharc

Deutsch (DE) (729.75 KB - PDF)

Amharc

eesti (ET) (742.82 KB - PDF)

Amharc

ελληνικά (EL) (925.35 KB - PDF)

Amharc

français (FR) (806.43 KB - PDF)

Amharc

italiano (IT) (763.73 KB - PDF)

Amharc

latviešu (LV) (1.23 MB - PDF)

Amharc

lietuvių (LT) (828.11 KB - PDF)

Amharc

magyar (HU) (1.17 MB - PDF)

Amharc

Malti (MT) (1.25 MB - PDF)

Amharc

Nederlands (NL) (710.35 KB - PDF)

Amharc

polski (PL) (1.24 MB - PDF)

Amharc

português (PT) (694.29 KB - PDF)

Amharc

română (RO) (864.44 KB - PDF)

Amharc

slovenčina (SK) (1.21 MB - PDF)

Amharc

slovenščina (SL) (1.15 MB - PDF)

Amharc

suomi (FI) (673.54 KB - PDF)

Amharc

svenska (SV) (659.25 KB - PDF)

Amharc

Íslenska (IS) (698.12 KB - PDF)

Amharc

norsk (NO) (729.88 KB - PDF)

Amharc
Latest procedure affecting product information:T/0038
24/04/2012
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (322.63 KB - PDF)

Amharc

español (ES) (271.5 KB - PDF)

Amharc

čeština (CS) (295.93 KB - PDF)

Amharc

dansk (DA) (268.04 KB - PDF)

Amharc

Deutsch (DE) (270.64 KB - PDF)

Amharc

eesti (ET) (264.04 KB - PDF)

Amharc

ελληνικά (EL) (286.07 KB - PDF)

Amharc

français (FR) (272.13 KB - PDF)

Amharc

italiano (IT) (270.35 KB - PDF)

Amharc

latviešu (LV) (297.31 KB - PDF)

Amharc

lietuvių (LT) (285.95 KB - PDF)

Amharc

magyar (HU) (285.79 KB - PDF)

Amharc

Malti (MT) (314.97 KB - PDF)

Amharc

Nederlands (NL) (264.39 KB - PDF)

Amharc

polski (PL) (300.21 KB - PDF)

Amharc

português (PT) (267.45 KB - PDF)

Amharc

română (RO) (295.26 KB - PDF)

Amharc

slovenčina (SK) (297.39 KB - PDF)

Amharc

slovenščina (SL) (281.9 KB - PDF)

Amharc

suomi (FI) (262.22 KB - PDF)

Amharc

svenska (SV) (273.16 KB - PDF)

Amharc

Íslenska (IS) (267.72 KB - PDF)

Amharc

norsk (NO) (266.44 KB - PDF)

Amharc

Product details

Name of medicine
Refludan
Active substance
lepirudin
International non-proprietary name (INN) or common name
lepirudin
Therapeutic area (MeSH)
  • Thromboembolism
  • Thrombocytopenia
Anatomical therapeutic chemical (ATC) code
B01AE02

Pharmacotherapeutic group

Antithrombotic agents

Therapeutic indication

Anticoagulation in adult patients with heparin-induced thrombocytopenia type II and thromboembolic disease mandating parenteral antithrombotic therapy.

The diagnosis should be confirmed by the heparin-induced platelet activation assay or an equivalent test.

Authorisation details

EMA product number
EMEA/H/C/000122
Marketing authorisation holder
Celgene Europe Ltd.

Riverside House
Riverside Walk
Windsor
Berkshire
SL4 1NA
United Kingdom

Marketing authorisation issued
13/03/1997
Withdrawal of marketing authorisation
24/04/2012
Revision
15

Assessment history

This page was last updated on

Share this page